MUSK and myasthenia gravis: Of note, miR-151a-3p was reduced in MuSK-MG patients treated with rituximab, a monoclonal antibody targeting CD20 expressed in B cells, after a six-month treatment in which clinical severity scores were reduced [103], leading to the hypothesizing of a relationship between MuSK-MG-associated miR-151a-3p increase, B cells, and disease pathogenesis.